Artivion, Inc. (NYSE:AORT) Receives Average Rating of “Moderate Buy” from Analysts

Artivion, Inc. (NYSE:AORT) has been given a consensus recommendation of “Moderate Buy” by the nine analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $49.1143.

Several research analysts have recently issued reports on AORT shares. Needham & Company LLC restated a “buy” rating and issued a $58.00 price target on shares of Artivion in a research report on Monday, February 2nd. Canaccord Genuity Group restated a “buy” rating and set a $51.00 target price on shares of Artivion in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, January 21st. Citizens Jmp increased their price target on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Finally, Oppenheimer restated an “outperform” rating and set a $50.00 price objective on shares of Artivion in a report on Friday, November 7th.

Insider Buying and Selling

In other Artivion news, CAO Amy Horton sold 6,000 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $45.73, for a total value of $274,380.00. Following the completion of the sale, the chief accounting officer directly owned 135,380 shares in the company, valued at $6,190,927.40. This represents a 4.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Marshall S. Stanton sold 47,376 shares of the firm’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $45.04, for a total value of $2,133,815.04. Following the sale, the senior vice president directly owned 44,753 shares in the company, valued at approximately $2,015,675.12. This represents a 51.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 128,448 shares of company stock worth $5,793,361 over the last ninety days. Insiders own 7.60% of the company’s stock.

Institutional Trading of Artivion

Large investors have recently bought and sold shares of the business. MetLife Investment Management LLC raised its holdings in Artivion by 2.7% during the 4th quarter. MetLife Investment Management LLC now owns 23,056 shares of the company’s stock worth $1,052,000 after buying an additional 606 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Artivion by 0.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 980,837 shares of the company’s stock worth $44,737,000 after acquiring an additional 7,817 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in shares of Artivion during the fourth quarter worth $183,000. New York State Common Retirement Fund lifted its position in Artivion by 0.8% in the 4th quarter. New York State Common Retirement Fund now owns 84,446 shares of the company’s stock valued at $3,852,000 after acquiring an additional 692 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in Artivion by 35.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 840,062 shares of the company’s stock worth $38,315,000 after purchasing an additional 217,860 shares during the period. 86.37% of the stock is owned by institutional investors.

Artivion Stock Up 1.5%

Shares of NYSE:AORT opened at $40.71 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -169.63 and a beta of 1.59. The company has a 50 day moving average of $43.76 and a 200-day moving average of $42.75. Artivion has a one year low of $21.97 and a one year high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The business had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. The firm’s quarterly revenue was up 19.2% compared to the same quarter last year. On average, sell-side analysts forecast that Artivion will post 0.37 earnings per share for the current year.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.